Researchers have discovered the reason why targeted treatment for non-small cell lung cancer fails to work for some patients, particularly those who have never smoked.
The study shows that lung cancer cells with two particular genetic mutations are more likely to double their genome, which helps them to withstand treatment and develop resistance to it. Conducted by researchers from UCL, the Francis Crick Institute, and AstraZeneca, the study is published today (June 13) in the journal Nature Communications.
Epidemiology and Genetic Factors of NSCLC
In the UK, lung cancer is the third most common type of cancer and the leading cause of cancer death. Around 85% of patients with lung cancer have non-small cell lung cancer (NSCLC), and this is the most common type found in patients who have never smoked. Considered separately, ‘never smoked’ lung cancer is the fifth most common cause of cancer death in the world.
The most common genetic mutation found in NSCLC is in the epidermal growth factor receptor gene (EGFR), which enables cancer cells to grow faster. It is found in about 10-15% of NSCLC cases in the UK, particularly in patients who have never smoked.
Challenges of Current Treatments
Survival rates vary depending on how advanced the cancer is, with only around a third of patients with Stage IV NSCLC and an EGFR mutation surviving for up to three years.
Lung cancer treatments that target this mutation, known as EGFR inhibitors, have been available for over 15 years. However, while some patients see their cancer tumors shrink with EGFR inhibitors, other patients, particularly those with an additional mutation in the p53 gene (which plays a role in tumor suppression), fail to respond and experience far worse survival rates. But scientists and clinicians have so far been unable to explain why this is the case.
Insights From New Research
To find the answer, the researchers re-analyzed data from trials of the newest EGFR inhibitor, Osimertinib, developed by AstraZeneca. They looked at baseline scans and first follow-up scans taken a few months into treatment for patients with either EGFR-only or with EGFR and p53 mutations.
The team compared every tumor on the scans, far more than were measured in the original trial. They found that for patients with just the EGFR mutations, all tumors got smaller in response to treatment. But for patients with both mutations, while some tumors had shrunk others had grown, providing evidence of rapid drug resistance. This pattern of response, when some but not all areas of a cancer are shrinking in response to a drug treatment within an individual patient, is known as a ‘mixed response’ and is a challenge for oncologists caring for patients with cancer.
Study Findings and Future Implications
To investigate why some tumors in these patients might be more prone to drug resistance, the team then studied a mouse model with both the EGFR and p53 mutation. They found that within resistant tumors in these mice, far more cancer cells had doubled their genome, giving them extra copies of all their chromosomes.
The researchers then treated lung cancer cells in the lab, some with just the single EGFR mutation and some with both mutations, with an EGFR inhibitor. They found that within five weeks of exposure to the drug, a significantly higher percentage of cells with both the double mutation and double genomes had multiplied into new drug-resistant cells.
Toward Better Diagnostic Tools
Professor Charles Swanton, from UCL Cancer Institute and the Francis Crick Institute, said: “We’ve shown why having a p53 mutation is associated with worse survival in patients with non-smoking related lung cancer, which is the combination of EGFR and p53 mutations enabling genome doubling. This increases the risk of drug-resistant cells developing through chromosomal instability.”
Non-small cell lung cancer patients are already tested for EGFR and p53 mutations, but there is currently no standard test to detect the presence of whole genome doubling. The researchers are already looking to develop a diagnostic test for clinical use.
Clinical Applications and Future Research
Dr. Crispin Hiley, from UCL Cancer Institute and a Consultant Clinical Oncologist at UCLH, said: “Once we can identify patients with both EGFR and p53 mutations whose tumours display whole genome doubling, we can then treat these patients in a more selective way. This might mean more intensive follow up, early radiotherapy or ablation to target resistant tumors, or early use of combinations of EGFR inhibitors, such as Osimertinib, with other drugs including chemotherapy.”
Reference: “Heterogeneous responses to EGFR tyrosine kinase inhibition in non-small cell lung cancer result from chromosomal instability facilitated by whole genome doubling and TP53 co-mutation” by Sebastijan Hobor, Maise Al Bakir, Crispin T. Hiley and Marcin Skrzypski et al., 13 June 2024, Nature Communications.
DOI: https://doi.org/10.1038/s41467-024-47606-9
This work was supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK, the UK Medical Research Council, and Wellcome.
News
NIH Scientists Discover Gene Responsible for Rare Eye Disease
Findings supported by the NIH pave the way for the development of genetic testing, clinical trials, and therapies. Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a gene linked to certain [...]
Alzheimer’s Breakthrough: Synthetic THC Pill Proves Effective in Clinical Trial
Patients tolerated synthetic THC (dronabinol) well, without the adverse effects commonly associated with existing Alzheimer’s agitation medications. A study conducted by researchers from Johns Hopkins University School of Medicine and Tufts University School of Medicine found that a pill form [...]
The Future of Rare Disease Treatment with Precision Medicine
Understanding rare diseases Rare diseases affect less than 5 people out of 10,000. However, this still amounts to about 7% of the world’s population, with over 10,000 such conditions. Almost all are genetic in [...]
Doctors issue warning for upcoming ‘tripledemic
The term ‘tripledemic’ has hit headlines this week as the NHS begins its Covid and fluvaccine roll-out for vulnerable adults. As the cold weather sets in, many of us have experienced a decline in health, and this may [...]
The FDA approved a gel that can stop bleeding from wounds in seconds
Aug 15 (Reuters) - The U.S. Food and Drug Administration has cleared Cresilon's gel to quickly control bleeding, the privately held company said on Thursday, potentially giving emergency medical technicians and combat medics a [...]
High levels of microplastics found in prostate tumors, possibly linked to take-out food
The presence of microplastics in prostate tumors points to potential health risks, and researchers are calling for urgent studies to explore how take-out food may be driving this exposure. In a recent study published [...]
AI outperforms radiologists in brain tumor diagnosis
As artificial intelligence advances, its uses and capabilities in real-world applications continue to reach new heights that may even surpass human expertise. In the field of radiology, where a correct diagnosis is crucial to ensure [...]
Breakthrough Study Reveals Molecular Clues to Dementia Origins
Work could lead to the discovery of new therapeutic targets. For the first time, researchers have identified “molecular markers” linked to degeneration—detectable changes in cells and their gene-regulating networks—that are common across several types [...]
Better than blood tests? Nanoparticle potential found for assessing kidneys
In a study published July 29 in Advanced Materials, University of Texas at Dallas researchers found that X-rays of the kidneys using gold nanoparticles as a contrast agent might be more accurate in detecting kidney [...]
Greener nanomaterials could transform how our everyday stuff is made
Tiny nanoparticles are at the forefront of materials science—with special properties that make them great at absorbing light in solar panels, cleaning wastewater, and delivering drugs precisely. Some nanoparticles take the form of sheets or fibers. But nanomaterials all [...]
AI could predict breast cancer risk via ‘zombie cells’
Women worldwide could see better treatment with new AI technology, which enables better detection of damaged cells and more precisely predicts the risk of getting breast cancer, shows new research from the [...]
Through the eyes of a cat – biomimicry of feline eyes may revolutionize robotic vision
In a recent study published in the journal Science Advances, researchers leveraged crucial aspects of feline eyes, particularly their tapetum lucidum and vertically elongated pupils (VP), to develop a monocular artificial vision system capable of [...]
New Alzheimer’s Therapy Shows Remarkable Results in Animal Trials
A study from TUM demonstrates a promising therapeutic approach. Researchers at the Technical University of Munich (TUM) have made promising advances in preventing Alzheimer’s by developing a new therapeutic strategy. Their approach focuses on targeting the amyloid beta [...]
Rewriting Cancer’s Blueprint: New Study Challenges Old Theories
A new study argues for a revised clonal evolution model of cancer, incorporating genetic and non-genetic factors to improve understanding and treatment. Like all living organisms, cancer cells are driven by the fundamental need [...]
Microplastics Everywhere: Experts Demand Worldwide Treaty Before It’s Too Late
A new report calls for global action on plastic pollution, urging reductions in plastic production and microplastic emissions. Researchers stress the importance of addressing plastic pollution through both scientific and social science perspectives. A [...]
Blood tests could soon predict your risk of Alzheimer’s
Scientists are closing in on biomarkers that reflect the progression of Alzheimer’s disease and could improve treatments. Like many Alzheimer’s researchers, neurologist Randall Bateman is not prone to effusiveness, having endured disappointments in his [...]
